Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/aps.2017.2 http://scihub22266oqcxt.onion/10.1038/aps.2017.2 C5520188!5520188 !28392568     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28392568 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Acta+Pharmacol+Sin 2017 ; 38 (6 ): 738-753 Nephropedia Template TP {{tp|p=28392568 |t=2017. Therapeutic gene editing: delivery and regulatory perspectives |pdf=|usr=}}{{28392568 }} gab.com Text Therapeutic gene editing: delivery and regulatory perspectives JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=28392568 #FOAvip Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence-specific engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases. However, strategies for precise engineering and delivery of gene-editing nucleases, including zinc finger nucleases, transcription activator-like effector nuclease, and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated nuclease Cas9), present major obstacles to the development of gene-editing therapies, as with other gene-targeting therapeutics. Currently, viral and non-viral vectors are being studied for the delivery of these nucleases into cells in the form of DNA, mRNA, or proteins. Clinical trials are already ongoing, and in vivo studies are actively investigating the applicability of CRISPR/Cas9 techniques. However, the concept of correcting the genome poses major concerns from a regulatory perspective, especially in terms of safety. This review addresses current research trends and delivery strategies for gene editing-based therapeutics in non-clinical and clinical settings and considers the associated regulatory issues. Twit Text FOAVip Therapeutic gene editing: delivery and regulatory perspectives ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=28392568 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28392568 #FOAvip English Wikipedia <ref>{{Cite pmid|28392568 }}</ref> Therapeutic gene editing: delivery and regulatory perspectives #MMPMID28392568 Shim G ; Kim D ; Park GT ; Jin H ; Suh SK ; Oh YK Acta Pharmacol Sin 2017[Jun]; 38 (6 ): 738-753 PMID28392568 show ga Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence-specific engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases. However, strategies for precise engineering and delivery of gene-editing nucleases, including zinc finger nucleases, transcription activator-like effector nuclease, and CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated nuclease Cas9), present major obstacles to the development of gene-editing therapies, as with other gene-targeting therapeutics. Currently, viral and non-viral vectors are being studied for the delivery of these nucleases into cells in the form of DNA, mRNA, or proteins. Clinical trials are already ongoing, and in vivo studies are actively investigating the applicability of CRISPR/Cas9 techniques. However, the concept of correcting the genome poses major concerns from a regulatory perspective, especially in terms of safety. This review addresses current research trends and delivery strategies for gene editing-based therapeutics in non-clinical and clinical settings and considers the associated regulatory issues. |*Gene Editing [MESH] |*Gene Transfer Techniques [MESH] |*Genetic Therapy [MESH] |Clustered Regularly Interspaced Short Palindromic Repeats/*genetics [MESH]Therapeutic gene editing: delivery and regulatory perspectives (epmc).pdf DeepDyve Pubget Overpricing